(Reuters) – U.S. health officials on Friday paused the distribution of Eli Lilly’s COVID-19 antibody therapies – bamlanivimab and etesevimab together and etesevimab alone – as they fail to show effectiveness against the Brazil and South Africa variants of the coronavirus.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)
